The US healthcare system is among the biggest contributors to the GDP of the country. The revenue for 2022 is estimated to be about $2,8 trillion (Statista). It is considered to be a mixed-insurance system with private insurance being the main player in the market. The government offers Medicare and Medicaid financing for certain categories of the population, mainly from income criteria. 

The fact that the healthcare system is mainly financed by the private market has both its advantages and disadvantages. The U.S. healthcare system is the most renowned for the high-level of medical care provision, with world leading research from well-known institutes and universities supporting the development of the industry. In addition to that, there are short waiting lines for treatment. Last but not least, given that the potential profit in this competitive market is great, it has resulted in economic efficiency and continuously improved resources. 

On the other hand, this system is characterized by high economic disparity as it excludes a considerable number of citizens from medical treatment. Almost 9% of the U.S. population is uninsured and they cannot afford the high cost of medical provision. Even citizens who have insurance sometimes cannot bear the cost of the insurance premium or they are not fully covered by their insurance program in some cases. As a result, they might skip recommended medical treatment or delay needed care. The past few years, with the Patient Protection and Affordable Care Act of 2010 the government has tried to popularize healthcare. 

The growth of the market in the proceeding years is almost guaranteed. Unfortunately, chronic diseases are estimated to increase, as well as challenges related to mental health.It is more than evident that the market offers revolutionary solutions for the patients to be quickly and efficiently treated. Thus, investment in R&D is crucial to support this high demand. A trend that is here to stay also is home treatment.

Pharmaceutical Industry. 

The U.S. is the top pharmaceutical industry with 45% of the global pharmaceutical market and 22% of the global pharmaceutical production. The continuously aging population is expected to raise the demand for drugs mid- and long-term making the industry very prominent for new entries.

The U.S. pharmacy market is projected to see a Compound Annual Growth Rate (CAGR) of 6.3% in forecast period, 2021-2028 (Fortune Business Insights).In 2021, the total revenue of the industry was estimated at about $550 billion. The top players in the retail pharmacy market are CVS Health Corporation, Walgreens Boots Alliance, Cigna, UnitedHealth Group,Walmart. 

Top pharmaceutical companies in the U.S. Johnson & Johnson, Pfizer Inc, Merck & CoAbbVie Inc.. There are also European pharmaceutical companies that have managed to conquer the U.S.market. Among them are AstraZeneca, Novo Nordisk, Roche. 

In order to enter the United States’ pharmaceutical market it is obligatory to follow the FDA’s rules and regulations. For each new product the companies have to submit the NDA or BLA applications and enclose information about manufacturing process, safety of the product, clinical trials etc. A typical review of each application takes about 10 months to be reviewed, but there are also additional processes that the product has to go through in order to be eventually launched to the market.. It is estimated that only about 10% of potential drugs make it through the meticulous process to become approved by the FDA. Nevertheless, the potentials of the market are great and can guarantee great return of investment. 

Medical devices. 

The medical devices market size was estimated at about $188.14 billion for 2021. Due to the aging population, the rise of population in general, and the rise in accessible healthcare by the “Obamacare” act, it is apparent that there is a huge demand for cost-effective medical devices.Though the United States hosts some of the largest med-tech corporations in the world there are still possibilities for companies especially from Canada, China, and Europe to develop on the industry. Good examples of successful european companies in the industry are Philips Healthcare who has highly evolved in med-tech and Siemens Healthinners who tries to advance cancer treatment.

FDA has a complex regulatory and device classification system that may prove overwhelming for some manufacturers. Let’s do a simple summary of the system:

Depending on the complexity of the product and the amount of risk that the patient-consumer might experience the devices are classified in 3 categories. In the first category (Class 1) 47% of the medical devices fall under, such as oximeters. These products are subject to “general controls”. In the second class more complicated devices are included (43% of the total devices) and they are subject to more strict rules than the first category. Some examples that fall into this umbrella of products are x-ray machines or fetal monitoring devices. Lastly, class 3 devices, like HIV diagnostics or pacemaker etc, require more complicated procedures and pre-market approval of safety and effectiveness. Companies have to provide a lot of data and operate clinical trials in order for their products to be approved by the FDA.